PDF herunterladen
Thromb Haemost 1989; 61(03): 459-462
DOI: 10.1055/s-0038-1646614
Original Article
Schattauer GmbH Stuttgart

Plasminogen Activator Inhibitor 1: A New Prognostic Marker in Septic Shock

Gerard Pralong
1   The Hematology Laboratory, Department of Medicine, University Hospital, Lausanne, Switzerland
,
Thierry Calandra
1   The Hematology Laboratory, Department of Medicine, University Hospital, Lausanne, Switzerland
,
Michel-P Glausef
2   The Division of Infectious Diseases, Department of Medicine, University Hospital, Lausanne, Switzerland
,
Joop Schellekens
3   The Department of Infectious Diseases, University Hospital Utrecht, The Netherlands
,
Jan Verhoef
3   The Department of Infectious Diseases, University Hospital Utrecht, The Netherlands
,
Fedor Bachmann
1   The Hematology Laboratory, Department of Medicine, University Hospital, Lausanne, Switzerland
,
Egbert K O Kruithof
1   The Hematology Laboratory, Department of Medicine, University Hospital, Lausanne, Switzerland
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 11. November 1988

Accepted after revision 24. Januar 1989

Publikationsdatum:
24. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The prognostic value of plasminogen activator inhibitor type 1 (PAI-1) in septic shock was investigated in 52 patients with septic shock. The patients had significantly elevated serum PAI-1 levels with respect to the control group (p = 0.002). In patients not having a rapidly fatal underlying disease, PAI-1 was significantly higher in patients dying within a week after onset of shock than in survivors (median PAI-1: 900 and 307 ng/ml, respectively; p = 0.001). The analysis of the distribution of PAI-1 levels permitted retrospectively to determine a threshold level of PAI-1 which had prognostic significance. Mortality was 71% in patients with serum PAI-1 above 550 ng/ml, whereas only two patients (6%) having a PAI-1 below 550 ng/ml died within a week.

Thus, in patients with septic shock, PAI-1 appears to have a strong predictive value as to mortality. This early marker may help the clinician in identifying a subgroup of patients particularly at risk.

Keywords

Plasminogen activator inhibitor type 1 - Septicemia - Septic shock
 

  • References

  • 1 McCabe WR, Jackson GG. Gram-negative bacteremia, I. Etiology and ecology. Arch Intern Med 1962; 110: 847-855
    CrossrefPubMedGoogle Scholar
  • 2 Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia, IV. Re-evaluation of clinical features and treatement in 612 Patients. Am J Med 1980; 68: 344-355
    CrossrefPubMedGoogle Scholar
  • 3 Ziegler EJ, McCutchan JA, Fierer J. et al Treatment of Gramnegative bacteremia and shock with human antiserum to mutant E. coli. N Engl J Med 1982; 307: 1225-1230
    CrossrefPubMedGoogle Scholar
  • 4 Parker MM, Parillo JE. Septic shock: hemodynamics and pathogenesis. J Am Med Assoc 1983; 250: 3324-3327
    CrossrefPubMedGoogle Scholar
  • 5 Shubin H, Weil MH. Bacterial shock. J Am Med Assoc 1976; 235: 421-424
    CrossrefPubMedGoogle Scholar
  • 6 Bone RC, Fisher CJ, Clemmer TP. et al A controlled clinical trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658
    CrossrefPubMedGoogle Scholar
  • 7 Smith-Erichsen N, Aasen AO, Gallimore MJ, Amundsen E. Studies of components of the coagulation systems in normal individuals and septic shock patients. Circ Shock 1982; 9: 491-497
    PubMedGoogle Scholar
  • 8 Hellgren M, Egberg N, Eklund J. Blood coagulation and fibrinolytic factors and their inhibitors in critically ill patients. Intensive Care Med 1984; 10: 23-28
    PubMedGoogle Scholar
  • 9 Bachmann F. Fibrinolysis In: Verstraete M, Vermylen J, Lijnen R, Arnout J. (eds) Thrombosis and Haemostasis 1987. University Press; Leuven: 1987. pp 227-265
  • 10 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-436
    CrossrefPubMedGoogle Scholar
  • 11 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
    PubMedGoogle Scholar
  • 12 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
    CrossrefPubMedGoogle Scholar
  • 13 Kruithof EK O, Tran-Thang C, Bachmann F. Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemostas 1986; 55: 201-205
    PubMedGoogle Scholar
  • 14 Kruithof EK O, Nicoloso G, Bachmann F. Plasminogen activator inhibitor 1 Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-1653
    PubMedGoogle Scholar
  • 15 Colucci M, Paramo JA, Collen D. Generation in plasma of a fastacting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-824
    CrossrefPubMedGoogle Scholar
  • 16 Engebretsen LF, Kierulf P, Brandtzaeg P. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res 1986; 42: 713-716
    CrossrefPubMedGoogle Scholar
  • 17 Calandra T, Glauser MP, Schellekens J. et al Treatment of Gramnegative septic shock with human E. coli J5 immunoglobulin G J Infect Dis 1988; 158: 312-319
    CrossrefPubMedGoogle Scholar
  • 18 Kruskal WH, Wallis WA. J Am Statist Assoc 1952; 583
    PubMed
  • 19 Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med 1987; 316: 379-385
    CrossrefPubMedGoogle Scholar
  • 20 Tracey KJ, Beutler B, Lowry SF. et al Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474
    CrossrefPubMedGoogle Scholar
  • 21 Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1: 355-357
    PubMedGoogle Scholar
  • 22 Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-867
    CrossrefPubMedGoogle Scholar
  • 23 Tracey KJ, Fong Y, Hesse DG. et al Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 1987; 330: 662-664
    CrossrefPubMedGoogle Scholar
  • 24 Dinarello CA, Cannon JG, Wolff SM. et al Tumor necrosis factor is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433-1450
    CrossrefPubMedGoogle Scholar
  • 25 Dubor F, Dosne AM, Chedid L. Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture. Infect Immunol 1986; 52: 725-729
    PubMedGoogle Scholar
  • 26 Crutchley DJ, Conanan LB. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem 1986; 261: 154-159
    PubMedGoogle Scholar
  • 27 Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
    CrossrefPubMedGoogle Scholar
  • 28 Nachmann RL, Hajjar KA, Silverstein KL. et al Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J Exp Med 1986; 163: 1595-1600
    CrossrefPubMedGoogle Scholar
  • 29 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor J Biol Chem 1988; 263: 5797-5803
    PubMedGoogle Scholar
  • 30 Van Hinsbergh VW M, Kooistra T, Van den Berg EA, Princen HM G, Fiers W, Emeis JJ. Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo. Blood 1988; 72: 1467-1473
    PubMedGoogle Scholar
  • 31 Medcalf RL, Kruithof EK O, Schleuning WD. Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin responsive genes. J Exp Med 1988; 168: 751-759
    CrossrefPubMedGoogle Scholar
  • 32 Phillips LL, Margaretten W, McKay DG. Changes in the fibrinolytic enzyme system following intravascular coagulation induced by thrombin and endotoxin. Am J Obstet Gynecol 1968; 100: 319-326
    CrossrefPubMedGoogle Scholar
  • 33 Bergstein JM, Michael AF. Renal cortical fibrinolytic activity in the rabbit following one or two doses of endotoxin. Thromb Diathes Haemorrh 1973; 29: 27-32
    PubMedGoogle Scholar
  • 34 Colucci M, Balconi G, Lorenzet R. et al Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893-1896
    CrossrefPubMedGoogle Scholar
  • 35 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745
    CrossrefPubMedGoogle Scholar
  • 36 Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant activity in cultivated vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986; 83: 4533-4537
    CrossrefPubMedGoogle Scholar
  • 37 Krishnamurti C, Barr CF, Hassett MA, Young GD, Alving BM. Plasminogen activator inhibitor: a regulator of ancrod induced fibrin deposition in rabbits. Blood 1987; 69: 798-803
    PubMedGoogle Scholar
  • 38 Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K, Mori J. Recombinant human tumor necrosis factor a: thrombus formation is a cause of anti-tumor activity. Int J Cancer 1988; 41: 243-247
    CrossrefPubMedGoogle Scholar
  • 39 Hamsten A, De Faire U, Walldius G. et al Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2 (04) 3-8
    PubMedGoogle Scholar
  • 40 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1456
    CrossrefPubMedGoogle Scholar
  • 41 Juhan-Vague I, Valadier J, Alessi MC. et al Deficient t-PA release and elevated PA-inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
    PubMedGoogle Scholar